INT311977

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.79
Pain Relevance 0.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

IFNA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Sicca syndrome 10 98.32 Very High Very High Very High
rheumatoid arthritis 38 95.96 Very High Very High Very High
Infliximab 13 90.36 High High
Etanercept 3 89.40 High High
Multiple sclerosis 72 87.84 High High
antagonist 3 77.16 Quite High
Inflammation 19 73.68 Quite High
chemokine 2 42.56 Quite Low
methotrexate 7 22.72 Low Low
cytokine 22 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Syndrome 14 98.32 Very High Very High Very High
Recurrence 31 96.64 Very High Very High Very High
Rheumatoid Arthritis 38 95.96 Very High Very High Very High
Lipodystrophy 2 93.04 High High
Cognitive Disorder 2 89.60 High High
Multiple Sclerosis 28 87.84 High High
Toxicity 2 82.76 Quite High
Demyelinating Disease 52 82.28 Quite High
Systemic Lupus Erythematosus 9 80.52 Quite High
INFLAMMATION 23 73.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An expansion of naïve Treg has been described in Glatiramer Acetate treatment [26], and a decrease of memory Treg cells in IFN-?
Regulation (described) of Negative_regulation (decrease) of IFN
1) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3001453 Disease Relevance 0.17 Pain Relevance 0.04
Two trials suggested a benefit of SC IFN?
Regulation (suggested) of Negative_regulation (benefit) of IFN
2) Confidence 0.10 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938285 Disease Relevance 0.75 Pain Relevance 0.14
The differences between the effects of TNF blockade on IFN response activity between the studies in SS [11] and SoJIA [9], on the one hand, and our studies in RA and spondyloarthritis (SpA) [31], on the other, could have their origin in differences in design between the studies, such as the use of infliximab in RA versus etanercept in SS, and the different readout systems used.
Regulation (effects) of Negative_regulation (blockade) of IFN associated with infliximab, sicca syndrome, rheumatoid arthritis and etanercept
3) Confidence 0.06 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875639 Disease Relevance 0.87 Pain Relevance 0.46

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox